Welcome to our dedicated page for BLDEW SEC filings (Ticker: BLDEW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on BLDEW's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into BLDEW's regulatory disclosures and financial reporting.
Strata Critical Medical, Inc. Co-CEO and CFO William A. Heyburn reported a Form 4 transaction involving company Class A common stock. On June 8, 2026, 31,671 shares were surrendered at a price of $5.87 per share. According to the footnote, these shares were withheld by the company to cover tax withholding obligations tied to the vesting of restricted stock units, rather than sold in the open market. After this tax-related share withholding, Heyburn held 1,548,997 shares directly, indicating he retained a substantially larger equity position in the company.
Strata Critical Medical, Inc. Co-CEO and CFO William A. Heyburn reported a Form 4 transaction involving company Class A common stock. On June 8, 2026, 31,671 shares were surrendered at a price of $5.87 per share. According to the footnote, these shares were withheld by the company to cover tax withholding obligations tied to the vesting of restricted stock units, rather than sold in the open market. After this tax-related share withholding, Heyburn held 1,548,997 shares directly, indicating he retained a substantially larger equity position in the company.
Strata Critical Medical, Inc. Chief Accounting Officer Cohen Amir reported an open-market sale of Class A common stock. On June 8, 2026, he sold 4,655 shares at $5.87 per share. After this transaction, he directly holds 146,608 shares of the company’s common stock.
Strata Critical Medical, Inc. Chief Accounting Officer Cohen Amir reported an open-market sale of Class A common stock. On June 8, 2026, he sold 4,655 shares at $5.87 per share. After this transaction, he directly holds 146,608 shares of the company’s common stock.
Strata Critical Medical, Inc. director and Co-CEO Melissa M. Tomkiel reported an open-market sale of 29,730 shares of Class A common stock at $5.87 per share on June 8, 2026. Following this transaction, she directly holds 1,892,774 shares of the company’s Class A common stock.
Strata Critical Medical, Inc. director and Co-CEO Melissa M. Tomkiel reported an open-market sale of 29,730 shares of Class A common stock at $5.87 per share on June 8, 2026. Following this transaction, she directly holds 1,892,774 shares of the company’s Class A common stock.
Strata Critical Medical, Inc. CEO of Logistics Scott M. Wunsch reported an open-market sale of 5,550 shares of Class A common stock at $5.87 per share. After this sale, he holds 625,574 shares directly and 382,987 shares indirectly through a limited liability company of which he is the sole member.
Strata Critical Medical, Inc. CEO of Logistics Scott M. Wunsch reported an open-market sale of 5,550 shares of Class A common stock at $5.87 per share. After this sale, he holds 625,574 shares directly and 382,987 shares indirectly through a limited liability company of which he is the sole member.
Strata Critical Medical, Inc. reported results of its annual stockholder meeting held on May 28, 2026. Stockholders elected Class II directors William A. Heyburn and Andrew Lauck to serve until the 2029 annual meeting. Heyburn received 46,050,902 votes for and 505,421 withheld, while Lauck received 39,525,159 for and 7,031,164 withheld, with 12,687,496 broker non-votes for each.
Stockholders also ratified Deloitte & Touche LLP as independent registered public accounting firm for the year ending December 31, 2026, with 58,946,832 votes for, 65,815 against, and 231,172 abstentions. In an advisory vote, stockholders approved executive compensation with 38,497,962 votes for, 8,022,682 against, 35,679 abstentions, and 12,687,496 broker non-votes.
Strata Critical Medical, Inc. reported results of its annual stockholder meeting held on May 28, 2026. Stockholders elected Class II directors William A. Heyburn and Andrew Lauck to serve until the 2029 annual meeting. Heyburn received 46,050,902 votes for and 505,421 withheld, while Lauck received 39,525,159 for and 7,031,164 withheld, with 12,687,496 broker non-votes for each.
Stockholders also ratified Deloitte & Touche LLP as independent registered public accounting firm for the year ending December 31, 2026, with 58,946,832 votes for, 65,815 against, and 231,172 abstentions. In an advisory vote, stockholders approved executive compensation with 38,497,962 votes for, 8,022,682 against, 35,679 abstentions, and 12,687,496 broker non-votes.
Strata Critical Medical, Inc. Chief Accounting Officer Amir Cohen reported open-market sales of company Class A common stock. On May 22, 2026, he sold 40,575 shares at a weighted average price of $5.91 per share. On May 21, 2026, he sold an additional 10,300 shares at a weighted average price of $5.79 per share. After these transactions, Cohen directly held 151,263 shares of Class A common stock. The filing notes that at least one of the transactions was executed under a pre-arranged Rule 10b5-1 trading plan, indicating the sales were scheduled in advance.
Strata Critical Medical, Inc. Chief Accounting Officer Amir Cohen reported open-market sales of company Class A common stock. On May 22, 2026, he sold 40,575 shares at a weighted average price of $5.91 per share. On May 21, 2026, he sold an additional 10,300 shares at a weighted average price of $5.79 per share. After these transactions, Cohen directly held 151,263 shares of Class A common stock. The filing notes that at least one of the transactions was executed under a pre-arranged Rule 10b5-1 trading plan, indicating the sales were scheduled in advance.
Strata Critical Medical, Inc. Chief Accounting Officer Amir Cohen sold 14,306 shares of Class A common stock on May 11, 2026 in an open-market sale at a weighted average price of $5.79 per share. The transaction was executed under a Rule 10b5-1 trading plan adopted on December 10, 2025. Following this sale, Cohen directly holds 202,138 shares of the company’s Class A common stock.
Strata Critical Medical, Inc. Chief Accounting Officer Amir Cohen sold 14,306 shares of Class A common stock on May 11, 2026 in an open-market sale at a weighted average price of $5.79 per share. The transaction was executed under a Rule 10b5-1 trading plan adopted on December 10, 2025. Following this sale, Cohen directly holds 202,138 shares of the company’s Class A common stock.
Morgan Stanley Smith Barney LLC submitted a Form 144 notice relating to proposed sales of Common stock tied to equity awards for the issuer with ticker BLDE. The excerpt lists 23,899 Restricted Stock Units dated 09/08/2024 and 41,282 Performance Stock Units dated 03/08/2025. The filing references 05/11/2026 and NASDAQ in the header.
Morgan Stanley Smith Barney LLC submitted a Form 144 notice relating to proposed sales of Common stock tied to equity awards for the issuer with ticker BLDE. The excerpt lists 23,899 Restricted Stock Units dated 09/08/2024 and 41,282 Performance Stock Units dated 03/08/2025. The filing references 05/11/2026 and NASDAQ in the header.
Velibor Krstic filed Amendment No. 3 to a Schedule 13D regarding Strata Critical Medical, Inc., reporting that 1,577,500 warrants to purchase Class A common stock (SRTAW) expired worthless on May 7, 2026.
Following this expiration, Krstic now beneficially owns 0 warrants, representing 0.0% of the warrant class, and therefore ceased to be a beneficial owner of more than five percent of these securities. The warrants had originally been purchased with personal funds, and no cash or other consideration was involved in their expiration.
Velibor Krstic filed Amendment No. 3 to a Schedule 13D regarding Strata Critical Medical, Inc., reporting that 1,577,500 warrants to purchase Class A common stock (SRTAW) expired worthless on May 7, 2026.
Following this expiration, Krstic now beneficially owns 0 warrants, representing 0.0% of the warrant class, and therefore ceased to be a beneficial owner of more than five percent of these securities. The warrants had originally been purchased with personal funds, and no cash or other consideration was involved in their expiration.
Strata Critical Medical, Inc. reported that Velibor Krstic, a ten percent owner, had 1,577,500 warrants to purchase Class A Common Stock expire. These warrants, exercisable at $11.50 per share, expired worthless on May 7, 2026 under a Warrant Agreement dated September 12, 2019. Following the expiration, no warrants of this series remain held by the reporting person.
Strata Critical Medical, Inc. reported that Velibor Krstic, a ten percent owner, had 1,577,500 warrants to purchase Class A Common Stock expire. These warrants, exercisable at $11.50 per share, expired worthless on May 7, 2026 under a Warrant Agreement dated September 12, 2019. Following the expiration, no warrants of this series remain held by the reporting person.